Edwards Lifesciences Corporation (NYSE: EW), a global leader in patient-choice innovations in structural heart disease and critical care monitoring, announced today that its senior management team will present at two upcoming investor conferences.
The presentations will offer insights into the company’s strategic priorities, ongoing advancements in transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid valve repair and replacement technologies, as well as its critical care portfolio. Investors can expect discussions on market dynamics, competitive landscapes, and the company’s robust pipeline, reflecting its commitment to addressing unmet patient needs with pioneering solutions.
**Barclays Global Healthcare Conference**
The company will participate in the Barclays Global Healthcare Conference. The presentation is scheduled for **Monday, March 11, 2024, at 9:45 AM EST**. Management will likely delve into the expanding opportunities within the structural heart market, particularly the TAVR segment, which continues to see significant growth driven by technological innovation and increasing physician and patient adoption. Discussions may also touch upon the company’s progress with its next-generation TAVR systems, such as the Edwards SAPIEN 3 Ultra RESILIA™ valve, and its efforts to expand indications and access for patients worldwide. Furthermore, the critical care segment, encompassing advanced monitoring solutions for hemodynamics and respiratory function, will likely be highlighted for its contribution to improved patient outcomes in intensive care settings.
**Leerink Partners Global Healthcare Conference**
Following the Barclays event, Edwards Lifesciences will also present at the Leerink Partners Global Healthcare Conference. This presentation is slated for **Wednesday, March 13, 2024, at 10:00 AM EST**. At this forum, management is expected to provide a deeper dive into the company’s long-term growth drivers. This could include an overview of its research and development initiatives, clinical trial progress for upcoming technologies, and its strategy for navigating the evolving reimbursement landscape for cardiovascular interventions. The company’s commitment to innovation, underscored by its significant investment in R&D, positions it to capitalize on the growing demand for minimally invasive procedures and sophisticated patient monitoring tools. Analysts and investors will be looking for updates on the company’s competitive positioning against emerging technologies and established players, as well as its approach to expanding its global footprint and addressing diverse healthcare systems.
Webcasts of these presentations will be available on the Investor Relations section of the Edwards Lifesciences website at [https://ir.edwards.com](https://ir.edwards.com). A replay of the webcasts will be accessible for a limited time following the live events.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/18981.html
